Calidi Biotherapeutics (CLDI) Income from Non-Controlling Interests (2024 - 2025)
Calidi Biotherapeutics (CLDI) posted quarterly Income from Non-Controlling Interests of -$3000.0 for Q4 2025, up 94.12% year-over-year from -$1545.5 in Q4 2024, and up 90.62% quarter-over-quarter from -$32000.0 in Q3 2025.
Calidi Biotherapeutics (CLDI) Income from Non-Controlling Interests (2024 - 2025) Analysis & Trends
Calidi Biotherapeutics' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at -$3000.0 for Q4 2025.
- In Q4 2025, Income from Non-Controlling Interests rose 94.12% year-over-year to -$3000.0; the TTM figure through Dec 2025 stood at -$157000.0 (changed N/A YoY), while the FY2025 annual figure was -$157000.0, down 137.88% from the prior year.
- Income from Non-Controlling Interests for Q4 2025 stood at -$3000.0, up from -$32000.0 in the prior quarter.
- The five-year high for Income from Non-Controlling Interests was -$3000.0 in Q4 2025, with the low at -$76000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Calidi Biotherapeutics | 1.88 Mn | -2.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3,000.00 |
| Sep 30, 2025 | -32,000.00 |
| Jun 30, 2025 | -46,000.00 |
| Mar 31, 2025 | -76,000.00 |
| Dec 31, 2024 | -51,000.00 |
| Sep 30, 2024 | -15,000.00 |